Regeneron Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2012
Filed with the SEC on Jul 25, 2012 and accepted by EDGAR at Jul 25, 2012, 11:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2012-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2012-04-01 to 2012-06-30 | $304.4m | us-gaap:Revenues |
| Revenue | 6 months2012-01-01 to 2012-06-30 | $536.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2012-04-01 to 2012-06-30 | $21.8m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2012-01-01 to 2012-06-30 | $34.1m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2012-04-01 to 2012-06-30 | $147.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2012-01-01 to 2012-06-30 | $286.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2012-04-01 to 2012-06-30 | $47.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2012-01-01 to 2012-06-30 | $106.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2012-04-01 to 2012-06-30 | $87.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2012-01-01 to 2012-06-30 | $109.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2012-04-01 to 2012-06-30 | $11.2m | us-gaap:InterestExpense |
| Interest expense | 6 months2012-01-01 to 2012-06-30 | $22.4m | us-gaap:InterestExpense |
| Income tax | 3 months2012-04-01 to 2012-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2012-01-01 to 2012-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2012-04-01 to 2012-06-30 | $76.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2012-01-01 to 2012-06-30 | $88.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2012-04-01 to 2012-06-30 | $0.70 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2012-01-01 to 2012-06-30 | $0.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2012-04-01 to 2012-06-30 | $0.81 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2012-01-01 to 2012-06-30 | $0.94 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2012-04-01 to 2012-06-30 | 110,167,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2012-01-01 to 2012-06-30 | 108,998,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2012-01-01 to 2012-06-30 | −$165.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2012-01-01 to 2012-06-30 | $23.9m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2012-06-30 | $171.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2012-06-30 | $769.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2012-06-30 | $1.46bn | us-gaap:Assets |
| Current liabilities | At period end2012-06-30 | $183.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2012-06-30 | $862.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2012-06-30 | $594.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001206774-12-003062. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.